Today's Date: January 29, 2023
SPRUCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Spruce Power Holding Corp on Behalf of Long-Term Stockholders and   •   CREDITORS COMMITTEE FILES REORGANIZATION PLAN FOR DIOCESE OF ROCKVILLE CENTRE; DIOCESE OF ROCKVILLE CENTRE FILES REORGANIZATION   •   CLEANSPARK INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers an   •   THE DIOCESE OF ROCKVILLE CENTRE FILES PLAN OF REORGANIZATION   •   AARP The Magazine Celebrates the 21st Annual Movies for Grownups® Awards   •   GENERAC DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Gen   •   Catholics for Choice on the Murder of Tyre Nichols: Black Lives Matter is a Pro-Life Issue   •   GINKGO BIOWORKS ALERT: Bragar Eagel & Squire, P.C. is Investigating Ginkgo Bioworks Holdings, Inc. on Behalf of Long-Term St   •   KIA AMERICA AND KIA GEORGIA CONTRIBUTE $100,000 TO THE AMERICAN RED CROSS OF GEORGIA IN SUPPORT OF TORNADO RELIEF INITIATIVES   •   PALANTIR TECHNOLOGIES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the   •   Susan G. Komen® Applauds House Introduction of Bipartisan Metastatic Breast Cancer Access to Care Act   •   Dollar General Announces 19,000th Store Opening   •   Black CannaBusiness CEO Intensive and Multi-State Cannabis Company Parallel Launch 2023 National Education Series in Pittsburgh   •   University of Phoenix College of Doctoral Studies Releases Whitepaper on Role of Demographics in Career Optimism   •   Trusted reusable nappy retailer commits to nationwide incentive scheme and eco education for first-time parents   •   The International Fellowship of Christians and Jews Celebrating 40th Anniversary in 2023   •   Dame Shellie Hunt Founder of the Women of Global Change Honored with Humanitarian Doctorate in London   •   ZILLOW GROUP INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers   •   "Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representin   •   CORRECTING and REPLACING Vibrant Emotional Health Names Dr. Tia Dole as New Chief 988 Suicide & Crisis Lifeline Officer
Bookmark and Share

NEO INVESTOR ALERT: First and Only NeoGenomics Class Action Filed by Gibbs Law Group

OAKLAND, Calif. , January 25 /Businesswire/ - Gibbs Law Group reminds investors it has filed the first and only class action lawsuit against NeoGenomics, Inc. (NASDAQ: NEO) and certain of its officers and directors on behalf of investors who purchased NeoGenomics securities from February 27, 2020, through April 26, 2022, inclusive. Investors have until February 6, 2023, to apply to be appointed as a lead plaintiff in the lawsuit.

To join the NeoGenomics class action lawsuit or to speak privately with our legal team about your rights in this class action lawsuit, click here or contact us at 510-876-9368.

NeoGenomics provides cancer tests and testing services to doctors, clinics, hospitals, and pharmaceutical companies through its network of cancer testing laboratories in the United States, Europe, and Asia.

Allegations of Misconduct

According to the lawsuit, during the class period, Defendants made false and misleading statements or failed to disclose the following:

  1. Defendants represented to investors that it had a “comprehensive menu” of cancer tests with “every kind of testing modality that you can use for cancer, including some of the fast-growing new ones, like next-generation sequencing,” which positioned the Company as a “one-stop-shop” for pathologists and gave NeoGenomics “a competitive advantage” as a “go-to reference lab with a comprehensive menu for just about any kind of tests that you want to have done in cancer.”
  2. Defendants represented that NeoGenomics could “leverage” the supposedly “fixed cost” structure of its business to improve profitability as revenue increased and touted the Company’s “robust Compliance Program . . . to ensure compliance with the myriad of . . . laws, regulations and governmental guidance applicable to our business.”

The Truth Emerges

On November 4, 2021, NeoGenomics revealed that it was, “conducting an internal investigation with the assistance of outside counsel that focuses on the compliance of certain consulting and service agreements with federal healthcare laws and regulations” including “those relating to fraud, waste and abuse,” and had “accrued a reserve of $10.5 million for potential damage and liabilities associated with the federal healthcare program revenue received spanning multiple years.”

Next, on March 28, 2022, NeoGenomics disclosed the departure of its CEO “effective immediately” and simultaneously reduced its financial guidance largely due to “higher than anticipated” costs.

Finally, on April 27, 2022, NeoGenomics revealed that “higher payroll and payroll related costs” drove decreased profit and increased operating expenses, and admitted that its portfolio of cancer tests “is weighted to legacy” tests “while the market is moving towards larger, more comprehensive panels.” The Company further admitted that it had “not kept up” with competitors that were offering more in-demand technologically advanced cancer tests.

These disclosures caused the value of NeoGenomics stock to decline dramatically, resulting in significant harm to investors.

Since the lawsuit was filed, NeoGenomics subsidiary Inivata was also sued on December 21, 2022, for alleged patent infringement by genetic testing company Natera. NeoGenomics shares dropped 7% as a result, causing further harm to investors.

Then on January 19, 2023, NeoGenomics board member, David J. Daly, resigned, effective immediately.

About the NeoGenomics Class Action Lawsuit

The lawsuit, captioned Goldenberg v. NeoGenomics, Inc., No. 1:22-cv-10314, was filed in the U.S. District Court for the Southern District of New York and asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. If you suffered a loss in NeoGenomics, you have until February 6, 2023, to request that the Court appoint you as lead plaintiff. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any potential future recovery does not require that you serve as a lead plaintiff.

What Should NeoGenomics Investors Do?

To join the class action or discuss your legal rights in the NeoGenomics class action lawsuit, visit our website or contact our securities team directly at 510-876-9368.

About Gibbs Law Group

Gibbs Law Group represents investors throughout the country in securities litigation to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over two billion dollars for its clients against some of the world’s largest corporations, and our attorneys have received numerous honors for their work, including “Best Lawyers in America,” “Top Plaintiff Lawyers in California,” “California Lawyer Attorney of the Year,” “Class Action Practice Group of the Year,” “Consumer Protection MVP,” and “Top Women Lawyers in California.”

This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


STORY TAGS: Lawsuit, United States, North America, Class Action Lawsuit, Professional Services, Legal, California,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News